Evidence Table 112. KQ3—Dichotomous outcomes—Abnormal ECG

| **AuthorYear****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Reyes198459Parallel | N/A | Mixed:Low and/or Moderate | Hydrochlorothiazide(50) | Magnesium | 13 | NR | Placebo | 8 | NR | NR | Results state only that 'no statistically significant changes affected the electrocardiogram or the plasma variables studied during the trial'. Methods do not state which electrocardiographic measurements were taken. | Medium |
| Playford200358Parallel | N/A | At high risk for CHD | Fenofibrate(200) | Co-Q10 | 18 | NR | No Treatment | 17 | NR | NR |  | Low-medium |
| Di Spirito200819Crossover | N/A | At low risk for CHD (0-1 risk factors) | Atorvastatin (80) | Omega-3 | 50 |  | No Treatment | 50 |  | NR | No treatment related trends regarding ECG or other clinical or laboratory markers were found (no specific data) | Medium |
| McKenney200645Crossover | N/A | Mixed:Low and/or Moderate | Simvastatin (80) | Omega-3 | 24 |  | No Treatment | 24 |  | NR |  | Medium |
| Kim201035Crossover | N/A | Mixed:Low and/or Moderate | Ticlopidine (250 –single dose) | Gonkgo Biloba | 24 | 0 | No Treatment | 24 | 0 | NR |  | Medium |